01 March 2006
Results of severe sepsis treatment program using recombinant human activated protein C in Poland.
Andrzej Kübler, Ewa Mayzner-Zawadzka, Grażyna Durek, Wojciech Gaszyński, Ewa Karpel, Małgorzata Mikaszewska-Sokolewicz, Paweł MajakMed Sci Monit 2006; 12(3): CR107-112 :: ID: 447107
Abstract
Background: Recombinant human activated protein C (drotrecogin alfa [activated]- DAA) demonstrated in Phase III controlled clinical studies significant reduction of mortality in patientswith severe sepsis and high risk of death. The aim of the study was to assess the therapeutic efficacyof DAA in patients included in the National Severe Sepsis Register in Poland. Material/Methods: The analysisincluded 3233 cases of severe sepsis reported between 04.2003 and 11.2005. 302 patients (9.3%) were treatedwith DAA. The clinical course of the disease in DAA and non-DAA treatment groups was compared. Logisticregression models for the effects of independent variables on the risk of death (dependent variable)were developed. Results: In the patients treated with DAA, the relative risk of death was lower by 31%than in those who were not treated. In a multivariate logistic regression model, the use of DAA was,independently of the patient's age, severity of the clinical condition and type of organ dysfunction,the most significant mortality-reducing factor in severe sepsis. Conclusions: The use of DAA in the treatmentof severe sepsis proved to be a very effective method of mortality reduction. Controlled nationwide surveillanceprogram contributed to its effective utilization. The National Severe Sepsis Register proved to be avery useful instrument for assessment of the course of the disease and treatment efficacy.
Keywords: Sepsis - mortality, Registries, Recombinant Proteins - therapeutic use, Protein C - therapeutic use, Population Surveillance, Poland - epidemiology, Multivariate Analysis, Anti-Infective Agents - therapeutic use, Logistic Models, Intensive Care Units - statistics & numerical data, Hemorrhage - chemically induced, Evaluation Studies as Topic, APACHE
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952